'מערכת אימד'Smith PJ et.al.; Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1143-1156.
Abstract
Introduction: The first subcutaneous (SC) formulation of infliximab (IFX), CT‑P13 SC, has been approved in Europe and Australia, including for the treatment of inflammatory bowel disease (IBD).
Smith PJ, Fumery M, Leong RW, Novak K, Dignass A. Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1143-1156. doi: 10.1080/1744666X.2023.2231148. Epub 2023 Aug 13. PMID: 37382381.